ANXA2 and Adamantinomatous Craniopharyngioma: The expression of ANXA2 was extremely higher in recurrent Adamantinomatous Craniopharyngioma (AdaCPs) and ANXA2+ AdaCP cells were more sensitive to tyrosine kinase inhibitor gefitinib [35].